You have no items in your shopping cart.
ABSTRACT
Background: Alzheimer's disease (AD) is a neurodegenerative disorder that primarily affects the elderly population. Despite decades of research, there is currently no cure for AD, and available treatments only provide limited symptomatic relief. Objective: The aim is to assess the impact of N-Acetylglucosamine (GlcNAc) treatment on cognitive function and potassium channel gene expression in the cerebellum and cortex, comparing it with Donepezil, a standard Alzheimer's disease treatment. Methods: Forty-five female Swiss albino mice were divided into five groups. Groups received either distilled water, various doses of N-Acetylglucosamine (GlcNAc), or Donepezil orally for 14 days. Scopolamine was administered to induce an Alzheimer's disease-like condition. Cognitive assessments (Y-Maze and Novel Object Recognition Test) were conducted, followed by gene expression analysis of potassium channels in the cerebellum and cortex. Results: The Y-Maze test showed no significant differences in cognitive performance among groups. However, in the Novel Object Recognition Test, N-Acetylglucosamine (GlcNAc)-treated groups demonstrated significant cognitive improvements compared to the control. In the cerebellum and cortex, N-Acetylglucosamine (GlcNAc) and Donepezil treatments significantly affected potassium channel gene expression, suggesting a potential mechanism for cognitive enhancement. Conclusion: N-Acetylglucosamine (GlcNAc) administration exhibited promising therapeutic benefits by improving cognitive function in an Alzheimer's disease-like condition. Additionally, it influenced potassium channel gene expression in both the cerebellum and cortex. These findings highlight the potential significance of N-Acetylglucosamine (GlcNAc) as a treatment option for Alzheimer's disease, warranting further research in this area.
